KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Non-Current Assets (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Non-Current Assets for 11 consecutive years, with $279.6 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 8.31% to $279.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Dec 2025, down 5.98% year-over-year, with the annual reading at $279.6 million for FY2025, 8.31% down from the prior year.
  • Non-Current Assets hit $279.6 million in Q4 2025 for CRISPR Therapeutics AG, down from $316.2 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $420.7 million in Q3 2022 to a low of $125.6 million in Q1 2021.
  • Historically, Non-Current Assets has averaged $316.6 million across 5 years, with a median of $320.4 million in 2023.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 244.29% in 2021 and later dropped 22.44% in 2023.
  • Year by year, Non-Current Assets stood at $334.4 million in 2021, then grew by 16.65% to $390.0 million in 2022, then dropped by 17.57% to $321.5 million in 2023, then fell by 5.16% to $304.9 million in 2024, then fell by 8.31% to $279.6 million in 2025.
  • Business Quant data shows Non-Current Assets for CRSP at $279.6 million in Q4 2025, $316.2 million in Q3 2025, and $296.0 million in Q2 2025.